Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life

Clotet B Feinberg J van Lunzen J et al . Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222–2231.

Rokx C Schurink C Boucher C et al . Dolutegravir as a maintenance monotherapy: first experiences in HIV-1 patients. J Antimicrob Chemother 2016; 71: 1632–1636.

Rojas J Blanco JL Marcos M et al . Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression. J Antimicrob Chemother 2016; 71: 1975–1981.

Katlama C Soulie C Caby F et al . Dolutegravir as monotherapy in HIV-1 infected individuals with suppressed HIV viraemia. J Antimicrob Chemother 2016; 71: 2646–2650.

Wijting I RoKx C Boucher C et al. Dolutegravir as maintenance monotherapy for HIV-1: a randomized clinical trial. In: Conference on retroviruses and opportunistic infections, Seattle, WA, 13–16 February 2017, abstract 451 LB.

Oldenbuettel C Wolf E Ritter A et al . Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther 2017; 22: 169–172.